Dr. Clay Flowers

Biography

Prior to joining TRANSFERRA, Dr. Flowers served as Director of Preclinical Development at INEX Pharmaceuticals Inc for eight years. There he was responsible for the non-clinical sections of four Investigational New Drug applications and one New Drug Application – Marqibo (liposomal vincristine) received regulatory approval in 2012.   Dr. Flowers received his doctorate at Louisiana State University Medical Center (Shreveport, LA) in Microbiology and Immunology for the  study of viral transcriptional programming and for the generation of a subunit vaccine targeting a neutralizing epitope of a viral receptor. Later as a Howard Hughes Medical Institute fellow at University of Michigan, he studied viral defense mechanisms for human immunodeficiency virus, modulators of nuclear factor kappa B, and viral gene function of the newly discovered human herpesvirus 8. Prior to joining TRANSFERRA, Dr. Flowers served as Director of Preclinical Development at INEX Pharmaceuticals Inc for eight years. There he was responsible for the non-clinical sections of four Investigational New Drug applications and one New Drug Application – Marqibo (liposomal vincristine) received regulatory approval in 2012.   Dr. Flowers received his doctorate at Louisiana State University Medical Center (Shreveport, LA) in Microbiology and Immunology for the  study of viral transcriptional programming and for the generation of a subunit vaccine targeting a neutralizing epitope of a viral receptor. Later as a Howard Hughes Medical Institute fellow at University of Michigan, he studied viral defense mechanisms for human immunodeficiency virus, modulators of nuclear factor kappa B, and viral gene function of the newly discovered human herpesvirus 8.

Research Interest

 Drug Discovery and Development  Pharmaceutical Technology and Biopharmaceutics Pharmaceutical Analysis